Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study

Cancer. 1979 Jul;44(1):48-51. doi: 10.1002/1097-0142(197907)44:1<48::aid-cncr2820440109>3.0.co;2-c.

Abstract

Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2.25 g/m2/day for 5 consecutive days. Courses were repeated every three weeks. Regressions were noted in 9 of 84 treated patients (11%). Median survival for all patients was 32 weeks. Responders survived only 5 weeks longer than nonresponders; 36 vs. 31 weeks. Central nervous system toxicity was a limiting factor occurring in one-third of patients. Ftorafur in a daily X5 schedule appears not to make a significant contribution to the management of disseminated colorectal cancer.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adult
  • Aged
  • Central Nervous System / drug effects
  • Colonic Neoplasms / drug therapy*
  • Drug Evaluation
  • Female
  • Fluorouracil / analogs & derivatives*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Rectal Neoplasms / drug therapy*
  • Remission, Spontaneous
  • Tegafur / adverse effects
  • Tegafur / pharmacology*
  • Time Factors

Substances

  • Tegafur
  • Fluorouracil